Want to see EWTX full AI Analyst Report?
Top Page
Edgewise Therapeutics
(NASDAQ:EWTX)
Select Model
Select Model
Rating:54Neutral
Price Target:
$37.00
▼(-16.31% Downside)
Action:Reiterated
Date:09/24/26
The score is driven primarily by weak financial operating performance (no revenue, widening losses, and heavy cash burn), partially offset by a strong low-debt balance sheet. Technicals are mildly negative in the near term (below 20/50-day averages), and valuation signals remain challenged due to unprofitability and no dividend. A major positive is the asset sale providing substantial upfront cash that meaningfully improves financial flexibility.
Positive Factors
Low financial leverage
Extremely low leverage limits refinancing and interest-rate exposure while preserving financial flexibility for clinical development. The sizable equity base gives Edgewise a stronger solvency position than many development-stage biotechs, although continued losses remain a constraint.
Negative Factors
No commercial revenue
With no reported revenue, Edgewise remains dependent on financing, partnerships, or asset-related proceeds to fund operations rather than internally generated sales. This keeps the business model structurally pre-commercial and makes future financial performance highly dependent on clinical and regulatory execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Low financial leverage
Extremely low leverage limits refinancing and interest-rate exposure while preserving financial flexibility for clinical development. The sizable equity base gives Edgewise a stronger solvency position than many development-stage biotechs, although continued losses remain a constraint.
Read all positive factors
Edgewise Therapeutics (EWTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.27B
Dividend YieldN/A
Average Volume (3M)1.68M
Price to Earnings (P/E)―
Beta (1Y)1.71
Revenue GrowthN/A
EPS Growth-18.88%
CountryUS
Employees127
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.85
Shares Outstanding108,604,126
10 Day Avg. Volume1,455,227
30 Day Avg. Volume1,679,476
Financial Highlights & Ratios
PEG Ratio-1.23
Price to Book (P/B)4.89
Price to Sales (P/S)0.00
P/FCF Ratio-17.76
Enterprise Value/Market Cap0.92
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.64K
Enterprise Value/Ebitda-20.10
Forecast
1Y Price Target
$51.11Price Target Upside15.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-2.05
Revenue Forecast (FY)N/A
Edgewise Therapeutics Business Overview & Revenue Model
Company Description
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically enginee...
Edgewise Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
74
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -590.00K | -2.27M | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -194.89M | -165.53M | -131.52M | -98.43M | -63.08M | -42.54M |
| Net Income | -197.22M | -167.79M | -133.81M | -100.16M | -67.64M | -42.81M |
Balance Sheet | ||||||
| Total Assets | 479.69M | 552.60M | 486.82M | 340.04M | 367.10M | 285.23M |
| Cash, Cash Equivalents and Short-Term Investments | 460.71M | 530.11M | 470.17M | 318.39M | 351.95M | 280.79M |
| Total Debt | 3.59M | 3.99M | 4.74M | 5.41M | 4.41M | 0.00 |
| Total Liabilities | 31.61M | 30.35M | 27.60M | 21.20M | 20.39M | 10.85M |
| Stockholders Equity | 448.08M | 522.26M | 459.22M | 318.83M | 346.72M | 274.38M |
Cash Flow | ||||||
| Free Cash Flow | -159.62M | -143.82M | -110.34M | -97.69M | -58.18M | -34.17M |
| Operating Cash Flow | -159.42M | -143.82M | -109.03M | -91.95M | -52.63M | -33.51M |
| Investing Cash Flow | 166.40M | -32.79M | -184.66M | 102.89M | -70.58M | -242.23M |
| Financing Cash Flow | 8.72M | 196.09M | 249.25M | 53.17M | 129.64M | 186.38M |
Edgewise Therapeutics Technical Analysis
Neutral
44.21
Price Trends
41.84
Negative
40.86
Negative
35.93
Positive
Market Momentum
-0.79
Negative
47.12
Neutral
78.07
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EWTX, the sentiment is Neutral. The current price of 44.21 is above the 20-day moving average (MA) of 39.17, above the 50-day MA of 41.84, and above the 200-day MA of 35.93, indicating a neutral trend. The MACD of -0.79 indicates Negative momentum. The RSI at 47.12 is Neutral, neither overbought nor oversold. The STOCH value of 78.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for EWTX.
Edgewise Therapeutics Risk Analysis
Edgewise Therapeutics disclosed 87 risk factors in its most recent earnings report. Edgewise Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Edgewise Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $4.27B | -21.25 | -39.01% | ― | ― | -18.88% | |
54 Neutral | $5.06B | -123.65 | 21.72% | ― | -42.84% | -106.21% | |
52 Neutral | $5.05B | -12.53 | -160.19% | ― | ― | -14.40% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $1.87B | -12.31 | -9.96% | ― | -20.44% | -349.84% | |
47 Neutral | $2.92B | -4.69 | -64.30% | ― | ― | 13.71% | |
41 Neutral | $634.77M | -3.10 | -72.28% | ― | ― | 31.81% |
* Healthcare Sector Average
EWTX
Edgewise Therapeutics
39.31
23.28
145.23%
SRPT
Sarepta Therapeutics
17.73
-5.77
-24.55%
PTCT
PTC Therapeutics
60.59
-6.49
-9.68%
SLDB
Solid Biosciences
5.92
0.02
0.34%
SRRK
Scholar Rock Holding
41.49
10.99
36.03%
DYN
Dyne Therapeutics
15.62
-8.55
-35.37%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.